Verseon Corporation Verseon presents DME candidate at ARVO 2019
April 30 2019 - 1:02AM
RNS Non-Regulatory
TIDMVERS
Verseon Corporation
30 April 2019
Press release
April 30, 2019
Verseon Corporation
("Verseon" or the "Company")
Verseon presents oral drug candidate for diabetic eye disease
that could replace eye injections
Fremont, Calif.-Verseon presented promising preclinical data for
their first diabetic eye disease development candidate for clinical
trials at this week's ARVO 2019 annual meeting in Vancouver. This
new drug candidate for oral dosing could lead to the first real
alternative to eye injections, the current standard of care for
millions of diabetics at risk of losing their eye sight.
Diabetic macular edema (DME) is a leading cause of adult
blindness, affecting about one in three long-term diabetes
patients. With the prevalence of diabetes on the rise around the
globe, preventing complications like DME is becoming increasingly
urgent. However, the current standards of care for DME are regular
injections into the eye-treatments that are associated with side
effects including inflammation and infection and that work poorly
or not at all in about half of patients. Recent studies have also
shown that 25% of patients fail to follow up with their eye
injections, leaving them at risk of eventual vision loss.
Verseon's new development candidate, which is aimed for oral
administration, has the potential to fill a large unmet need for
both treatment and prevention of DME.
At ARVO 2019, Dr. Melissa Calton, Verseon's Program Manager of
Ophthalmology, presented preclinical data for the Company's lead
development candidate for clinical trials from their new class of
small-molecule plasma kallikrein inhibitors. In preclinical models,
the compound showed good efficacy against two important drivers of
the disease-the kallikrein and VEGF pathways-following
administration of a single oral dose.
"What's most exciting about our DME candidates isn't just that
they may replace eye injections, but that they could give doctors
an opportunity to prevent diabetes patients from developing DME in
the first place," said Dr. Calton. "Its excellent pharmacokinetic
profile sets our development candidate apart from other candidates,
making it suitable for administration as a pill. We are very
encouraged by our preclinical results and are working to bring this
candidate into clinical trials."
About Verseon's diabetic macular edema program
Verseon has developed a new class of potent, selective
small-molecule plasma kallikrein inhibitors for the treatment of
diabetic macular edema (DME), a major cause of adult blindness. In
contrast to current customary DME treatments that are administered
as recurring eye injections, Verseon develops drug candidates for
oral dosing. Several lead candidates have demonstrated efficacy in
reducing retinal thickening and retinal leakage, two hallmarks of
the disease, when administered orally. The Company is currently
preparing a first DME development candidate for phase 1 trials.
About Verseon
Verseon Corporation (www.verseon.com, AIM:VERS) is developing
disruptive life-science technology to advance global health. The
clinical-stage company is using its proprietary, computational drug
discovery platform to discover new drug candidates that are
unlikely to be found using conventional methods. Pairing its
computational platform with a comprehensive in-house chemistry and
biology workflow, the company has built a growing pipeline of drug
programs. Verseon currently has four active drug programs in the
areas of anticoagulation (currently in phase 1), diabetic macular
edema, hereditary angioedema, and oncology.
Find Verseon on Twitter and LinkedIn.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000
Arden Partners (NOMAD and Joint Broker)
Ruari McGirr / Ciaran Walsh / Alex +44 (0) 20 7614
Penney 5900
Cantor Fitzgerald Europe (Joint Broker)
+44 (0) 20 7894
Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers)
+44 (0) 20 7466
Henry Harrison-Topham / Jamie Hooper 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737 821
Simon Vane Percy 890
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKCDPBBKBQQB
(END) Dow Jones Newswires
April 30, 2019 02:02 ET (06:02 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024